MS patients may benefit from switching Immune-Suppressing drugs
NCT ID NCT06854094
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether switching from anti-CD20 drugs (like ocrelizumab) to cladribine can help restore immune function and reduce infections in people with relapsing multiple sclerosis. About 70 participants will be followed for 2 years. The goal is to see if the switch improves antibody levels and lowers infection risk compared to staying on anti-CD20 therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cladribine
What this could lead to
If successful, this could show that switching to cladribine helps restore immune function and lowers infection risk for MS patients on long-term anti-CD20 therapy.
What could go wrong
This is a relatively small study (70 people) and results may not apply to all MS patients. The switch might not improve immunity or could cause other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ospedale Regionale di Lugano, Istituto di Neuroscienze Cliniche della Svizzera Italiana, Via Tesserete 46,
Lugano, Canton Ticino, 6903, Switzerland